SIRPA and hematopoietic and lymphoid cell neoplasm: Blocking the CD47/SIRPα pathway had promising results in treatment of several solid tumors and hematological cancers such as glioblastoma, lymphoma, and breast cancer and may compel TAMs to phagocytose tumor cells (246, 248–255).